BMC Hematology最新文献

{"title":"Generic and disease-specific quality of life among youth and young men with Hemophilia in Canada.","authors":"J St-Louis,&nbsp;D J Urajnik,&nbsp;F Ménard,&nbsp;S Cloutier,&nbsp;R J Klaassen,&nbsp;B Ritchie,&nbsp;G E Rivard,&nbsp;M Warner,&nbsp;V Blanchette,&nbsp;N L Young","doi":"10.1186/s12878-016-0052-x","DOIUrl":"https://doi.org/10.1186/s12878-016-0052-x","url":null,"abstract":"<p><strong>Background: </strong>This study was undertaken to explore the longitudinal patterns of health-related quality of life (HRQoL) among youth and young adults with Hemophilia A (HA) over a 3-year period. This report presents the baseline characteristics of the study cohort.</p><p><strong>Methods: </strong>Males, 14 to 29 years of age, with predominantly severe HA were recruited from six treatment centres in Canada. Subjects completed a comprehensive survey. HRQoL was measured using: the CHO-KLAT2.0 (youth), Haemo-QoL-A (young adults) and the SF-36v2 (all).</p><p><strong>Results: </strong>13 youth (mean age = 15.7, range = 12.9-17.9 years) and 33 young adults (mean age = 23.6; range = 18.4 -28.7 years) with moderate (7 %) and severe (93 %) HA were enrolled. All were on a prophylactic regimen with antihemophilic factor (Helixate FS®) during the study. The youth had minimal joint damage (mean HJHS = 5.2) compared to young adults (mean HJHS = 13.3). The mean HRQoL scores for youth were: 79.2 (SD = 11.9) for the CHO-KLAT, and 53.0 (5.5) and 52.3 (6.8) for the SF-36 Physical Component Summary (PCS) and Mental Component Summary (MCS) scores respectively. The mean HRQoL scores for young adults were: 85.8 (9.5) for the Haemo-Qol-A, and 50.8 (6.4) and 50.9 (8.8) for PCS and MCS respectively. PCS and MCS scores were comparable to published Canadian norms, however significant differences were found for the domains of Physical Functioning and Bodily Pain. The disease-specific HRQoL scores were weakly correlated with the PCS for youth (CHO-KLAT vs. PCS r = 0.28, p = 0.35); and moderately correlated for the MCS (r = 0.39, p = 0.19). Haemo-QoL-A scores for young adults were strongly correlated with the PCS (r = 0.53, p = 0.001); and weakly correlated with the MCS (r = 0.26, p = 0.13). Joint status as assessed by HJHS was correlated with PCS scores. A history of lifelong prophylaxis resulted in better PCS but worse MCS scores.</p><p><strong>Conclusion: </strong>Despite having hemophilia, the youth in this cohort have minimal joint disease and good HRQoL. The young adults demonstrated more joint disease and slightly worse HRQoL in the domains of physical functioning and pain. The data presented here provide new information to inform the selection of Health Related Quality of Life (HRQoL) instruments for use in future clinical trials involving persons with hemophilia.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov : NCT01034904. Study funded by CSL Behring Canada.</p>","PeriodicalId":37740,"journal":{"name":"BMC Hematology","volume":"16 ","pages":"13"},"PeriodicalIF":0.0,"publicationDate":"2016-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12878-016-0052-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34530311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia.","authors":"Guillermo Garcia-Manero, Antonio Almeida, Aristoteles Giagounidis, Uwe Platzbecker, Regina Garcia, Maria Teresa Voso, Stephen R Larsen, David Valcarcel, Lewis R Silverman, Barry Skikne, Valeria Santini","doi":"10.1186/s12878-016-0049-5","DOIUrl":"10.1186/s12878-016-0049-5","url":null,"abstract":"<p><strong>Background: </strong>CC-486 is an oral formulation of the epigenetic modifier azacitidine. In an expanded phase 1 trial, CC-486 demonstrated clinical and biological activity in patients with International Prognostic Scoring System (IPSS) lower-risk (low- and intermediate-1-risk) myelodysplastic syndromes (MDS) with poor prognostic features including anemia and/or thrombocytopenia who may have required red blood cell or platelet transfusions. The overall response rate was 40 %, including hematologic improvement in 28 % of patients and RBC transfusion independence sustained for 56 days in 47 % of patients with baseline transfusion dependence. Based on the results of this study, the randomized, placebo-controlled phase 3 QUAZAR Lower-Risk MDS trial (AZA-MDS-003) was initiated. The design and rationale for this trial comparing CC-486 with placebo for the treatment of patients with IPSS lower-risk MDS with poor prognostic features are described.</p><p><strong>Methods: </strong>Patients must have IPSS lower-risk MDS with red blood cell (RBC) transfusion-dependent anemia and thrombocytopenia. Eligible patients are randomized 1:1 to receive 300 mg of CC-486 or placebo once daily for the first 21 days of 28-day treatment cycles. Disease status assessments occur at the end of cycle 6 and patients may continue to receive treatment unless there is evidence of progressive disease, lack of efficacy, or unacceptable toxicity. The primary endpoint is RBC transfusion independence for ≥ 84 days, assessed according to International Working Group 2006 criteria. Secondary endpoints include overall survival, hematologic response including platelet response and erythroid response, RBC transfusion independence for ≥ 56 days, duration of RBC transfusion independence, time to RBC transfusion independence, rate of acute myeloid leukemia (AML) progression, time to AML progression, clinically significant bleeding events, safety, health-related quality of life, and healthcare resource utilization.</p><p><strong>Conclusions: </strong>This study will provide data on the efficacy and safety of CC-486 in the treatment of IPSS lower-risk MDS with poor prognosis due to the presence of both RBC transfusion-dependent anemia and thrombocytopenia. Positive results of the AZA-MDS-003 study may expand treatment options for patients with IPSS lower-risk MDS.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov NCT01566695, registered March 27, 2012.</p>","PeriodicalId":37740,"journal":{"name":"BMC Hematology","volume":"16 ","pages":"12"},"PeriodicalIF":0.0,"publicationDate":"2016-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12878-016-0049-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34457262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kinetics of Langerhans cell chimerism in the skin of dogs following 2 Gy TBI allogeneic hematopoietic stem cell transplantation.","authors":"Sabrina Peters,&nbsp;Christian Junghanss,&nbsp;Anne Knueppel,&nbsp;Hugo Murua Escobar,&nbsp;Catrin Roolf,&nbsp;Gudrun Knuebel,&nbsp;Anett Sekora,&nbsp;Iris Lindner,&nbsp;Ludwig Jonas,&nbsp;Mathias Freund,&nbsp;Sandra Lange","doi":"10.1186/s12878-016-0050-z","DOIUrl":"https://doi.org/10.1186/s12878-016-0050-z","url":null,"abstract":"<p><strong>Background: </strong>Langerhans cells (LC) are bone marrow-derived cells in the skin. The LC donor/recipient chimerism is assumed to influence the incidence and severity of graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HSCT). In nonmyeloablative (NM) HSCT the appearance of acute GVHD is delayed when compared with myeloablative conditioning. Therefore, we examined the development of LC chimerism in a NM canine HSCT model.</p><p><strong>Methods: </strong>2 Gy conditioned dogs received bone marrow from dog leukocyte antigen identical littermates. Skin biopsies were obtained pre- and post-transplant. LC isolation was performed by immunomagnetic separation and chimerism analysis by PCR analyzing variable-number-of-tandem-repeat markers with subsequent capillary electrophoresis.</p><p><strong>Results: </strong>All dogs engrafted. Compared to peripheral blood chimerism the development of LC chimerism was delayed (earliest at day +56). None of the dogs achieved complete donor LC chimerism, although two dogs manifested a 100 % donor chimerism in peripheral blood at days +91 and +77. Of interest, one dog remained LC chimeric despite loss of donor chimerism in the peripheral blood cells.</p><p><strong>Conclusion: </strong>Our study indicates that LC donor chimerism correlates with chimerism development in the peripheral blood but occurs delayed following NM-HSCT.</p>","PeriodicalId":37740,"journal":{"name":"BMC Hematology","volume":"16 ","pages":"11"},"PeriodicalIF":0.0,"publicationDate":"2016-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12878-016-0050-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34503046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of chronic lymphocytic leukemia in Senegal.","authors":"Abibatou Sall, Awa Oumar Touré, Fatimata Bintou Sall, Moussa Ndour, Seynabou Fall, Abdoulaye Sène, Blaise Félix Faye, Moussa Seck, Macoura Gadji, Tandakha Ndiaye Dièye, Claire Mathiot, Sophie Reynaud, Saliou Diop, Martine Raphaël","doi":"10.1186/s12878-016-0051-y","DOIUrl":"10.1186/s12878-016-0051-y","url":null,"abstract":"<p><strong>Background: </strong>Chronic lymphocytic leukemia (CLL) is a mature B-cell neoplasm characterized by the expansion of CD5-positive lymphocytes in peripheral blood. While CLL is the most common type of leukemia in Western populations, the disease is rare in Africans. Hence, clinical and laboratory data and studies of CLL in Sub Saharan populations have been limited. The aims of this study were to analyze the characteristics of senegalese patients with CLL at the time of the diagnosis and to identify the correlation between clinical characteristics (Binet stage) with age, gender, laboratory parameters and chromosomal abnormalities.</p><p><strong>Methods: </strong>In this study, we investigated the clinical and laboratory characteristics of CLL in Senegal. A total of 40 patients who had been diagnosed with CLL during the period from July 2011 to April 2015 in Senegal were evaluated. Cytology and immunophenotype were performed in all patients to confirm the diagnosis. The prognosis factors such as Binet staging, CD38 and cytogenetic abnormalities were studied. The statistical analysis was performed using STATA version 13 (Stata college station Texas). Each patient signed a free and informed consent form before participating in the study.</p><p><strong>Results: </strong>The mean age was 61 years ranged from 48 to 85. There were 31 males and only 9 females (sex ratio M : F = 3,44). At diagnosic, 82.5 % of the patients were classified as having advanced Binet stages B or C. The prognosis marker CD38 was positive in 28 patients. Cytogenetic abnormalities studied by FISH were performed in 25 patients, among them, 68 % (17 cases) had at least one cytogenetic abnormality and 28 % had 2 simultaneous cytogenetic abnormalities.</p><p><strong>Conclusion: </strong>Africans may present with CLL at a younger age and our data suggest that CLL in Senegal may be more aggressive than in Western populations.</p>","PeriodicalId":37740,"journal":{"name":"BMC Hematology","volume":"16 ","pages":"10"},"PeriodicalIF":0.0,"publicationDate":"2016-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841974/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34428417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endothelial fibrinolytic response onto an evolving matrix of fibrin.","authors":"O Castillo,&nbsp;H Rojas,&nbsp;Z Domínguez,&nbsp;E Anglés-Cano,&nbsp;R Marchi","doi":"10.1186/s12878-016-0048-6","DOIUrl":"https://doi.org/10.1186/s12878-016-0048-6","url":null,"abstract":"<p><strong>Background: </strong>Fibrin provides a temporary matrix at the site of vascular injury. The aims of the present work were (1) to follow fibrin formation and lysis onto the surface of human dermal microvascular endothelial cells (HMEC-1), and (2) to quantify the secretion of fibrinolytic components in the presence of fibrin.</p><p><strong>Methods: </strong>Fibrin clots at different fibrinogen concentrations were formed on top of (model 1) or beneath (model 2) the endothelial cells. Fibrin formation or lysis onto the surface of HMEC-1 cells, was followed by turbidity. Clot structure was visualized by laser scanning confocal microscopy (LSCM). The secretion of uPA and PAI-1 by HMEC-1 cells was quantified by ELISA.</p><p><strong>Results: </strong>The rate of fibrin formation increased approximately 1.5-fold at low fibrinogen content (0.5 and 1 mg/mL; p < 0.05) compared to the condition without cells; however, it was decreased at 2 mg/mL fibrinogen (p < 0.05) and no differences were found at higher fibrinogen concentrations (3 and 5 mg/mL). HMEC-1 retarded dissolution of clots formed onto their surface at 0.5 to 3 mg/mL fibrinogen (p < 0.05). Secretion of uPA was 13 × 10(-6) ng/mL per cell in the absence of RGD and 8 × 10(-6) ng/mL per cell in the presence of RGD, when clots were formed on the top of HMEC-1. However, the opposite was found when cells were grown over fibrin: 6 × 10(-6) ng/mL per cell without RGD vs. 17 × 10(-6) ng/mL per cell with RGD. The secretion of PAI-1 by HMEC-1 cells was unrelated to the presence of fibrin or RGD, 7 × 10(-6) μg/mL per cell and 5 × 10(-6) μg/mL per cell, for the apical (model 1) and basal clots (model 2), respectively.</p><p><strong>Conclusions: </strong>HMEC-1 cells influence fibrin formation and dissolution as a function of the fibrin content of clots. Clot degradation was accentuated at high fibrin concentrations. The secretion of fibrinolytic components by HMEC-1 cells seemed to be modulated by integrins that bind RGD ligands.</p>","PeriodicalId":37740,"journal":{"name":"BMC Hematology","volume":"16 ","pages":"9"},"PeriodicalIF":0.0,"publicationDate":"2016-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12878-016-0048-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34318137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of multiple myeloma presenting as a distal renal tubular acidosis with extensive bilateral nephrolithiasis","authors":"C. Fonseka, S. R. Galappaththi, Jeewandarage Dhanushka Karunarathna, D. Abeyaratne, N. Tissera","doi":"10.1186/s12878-016-0047-7","DOIUrl":"https://doi.org/10.1186/s12878-016-0047-7","url":null,"abstract":"","PeriodicalId":37740,"journal":{"name":"BMC Hematology","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12878-016-0047-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65891944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized double-blind safety comparison of intravenous iron dextran versus iron sucrose in an adult non-hemodialysis outpatient population: A feasibility study","authors":"M. Louzada, C. Hsia, F. Al-Ani, F. Ralley, A. Xenocostas, Janet E. Martin, Sarah E. Connelly, I. Chin-Yee, L. Minuk, A. Lazo-Langner","doi":"10.1186/s12878-016-0046-8","DOIUrl":"https://doi.org/10.1186/s12878-016-0046-8","url":null,"abstract":"","PeriodicalId":37740,"journal":{"name":"BMC Hematology","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12878-016-0046-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65891934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospitalization for pulmonary embolism associated with antecedent testosterone or estrogen therapy in patients found to have familial and acquired thrombophilia.","authors":"Marloe Prince, Charles J Glueck, Parth Shah, Ashwin Kumar, Michael Goldenberg, Matan Rothschild, Nasim Motayar, Vybhav Jetty, Kevin Lee, Ping Wang","doi":"10.1186/s12878-016-0045-9","DOIUrl":"10.1186/s12878-016-0045-9","url":null,"abstract":"<p><strong>Background: </strong>In patients hospitalized over a 4 year period for pulmonary embolism (PE), we assessed relationships of testosterone (TT) and estrogen therapy (ET) anteceding PE in patients found to have familial-acquired thrombophilia.</p><p><strong>Methods: </strong>From 2011 through 2014, 347 patients were hospitalized in Cincinnati Mercy Hospitals with PE. Retrospective chart review was used to identify patients receiving TT or ET before PE; coagulation studies were done prospectively if necessary.</p><p><strong>Results: </strong>Preceding hospitalization for PE, 8 of 154 men (5 %) used TT, and 24 of 193 women (12 %) used ET. The median number of months from the initiation of TT or ET to development of PE was 7 months in men and 18 months in women. Of the 6 men having coagulation measures, all had ≥ 1 thrombophilia, and of the 18 women having measures of coagulation, 16 had ≥ 1 thrombophilia. The sensitivity of a previous history of thrombosis to predict PE was low, 25 % (2/8 men), 4 % (1/24 women).</p><p><strong>Conclusions: </strong>Of 154 men hospitalized for PE, 8 (5 %) used TT, and of 193 women, 24 (12 %) used ET. Our data suggests that PE is an important complication of TT in men and ET in women, in part reflecting an interaction between familial and acquired thrombophilia and exogenous hormone use.</p>","PeriodicalId":37740,"journal":{"name":"BMC Hematology","volume":"16 1","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2016-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782383/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65891924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BMC Hematology reviewer acknowledgement 2015","authors":"Nawsheen Boodhun","doi":"10.1186/s12878-016-0044-x","DOIUrl":"https://doi.org/10.1186/s12878-016-0044-x","url":null,"abstract":"","PeriodicalId":37740,"journal":{"name":"BMC Hematology","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12878-016-0044-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65891883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The expression of embryonic globin mRNA in a severely anemic mouse model induced by treatment with nitrogen-containing bisphosphonate","authors":"H. Otsuka, J. Takito, Y. Endo, H. Yagi, S. Soeta, N. Yanagisawa, N. Nonaka, Masanori Nakamura","doi":"10.1186/s12878-016-0041-0","DOIUrl":"https://doi.org/10.1186/s12878-016-0041-0","url":null,"abstract":"","PeriodicalId":37740,"journal":{"name":"BMC Hematology","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12878-016-0041-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65891728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}